Beta-Lapachone


NQO1-bioactivatable ortho-naphthoquinone with selective tumor cytotoxicity through futile redox cycling and PARP1 hyperactivation

A naturally derived 1,2-naphthoquinone from the lapacho tree, bioactivated selectively by NAD(P)H:quinone oxidoreductase 1 to induce tumor-specific programmed necrosis through futile redox cycling, massive reactive oxygen species generation, DNA damage, PARP1 hyperactivation, and catastrophic NAD+/ATP depletion.

Abstract

Beta-lapachone is a naturally occurring ortho-naphthoquinone originally isolated from the heartwood of Tabebuia avellanedae (pau d’arco, lapacho) and synthesized from the prenylated naphthoquinone lapachol by acid-catalyzed cyclization. The compound is the canonical substrate of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2), a two-electron reductase that is overexpressed 5- to 100-fold in the majority of solid human cancers, including non-small cell lung, pancreatic ductal adenocarcinoma, breast, prostate, and head and neck squamous cell carcinomas, relative to matched normal tissue. NQO1-mediated two-electron reduction of beta-lapachone produces an unstable hydroquinone that spontaneously autoxidizes back to the parent quinone in a futile redox cycle consuming approximately 60 moles of NAD(P)H per mole of drug over a 2-hour exposure window. This cycle generates massive superoxide and hydrogen peroxide fluxes within the tumor cell, producing extensive oxidative DNA damage (predominantly single-strand breaks and oxidized bases) that triggers hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) in the presence of elevated nuclear calcium. PARP1 hyperactivation consumes the cellular NAD+ pool into branched poly(ADP-ribose) polymers, producing catastrophic NAD+ and ATP depletion, mu-calpain activation, apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus, and programmed necrosis that is mechanistically distinct from classical apoptosis and independent of caspase activation, p53 status, and Bcl-2 family protein expression. The NQO1 dependence of the cytotoxic mechanism confers tumor selectivity: NQO1-negative cells (including most normal tissues) are resistant to beta-lapachone at pharmacologically achievable concentrations, and dicoumarol (an NQO1 inhibitor) completely abrogates cytotoxicity in NQO1-positive cancer cell lines. Beta-lapachone was advanced into clinical development as ARQ 501 (an intravenous hydroxypropyl-beta-cyclodextrin inclusion complex) by ArQule, Inc. and subsequently as ARQ 761 (an improved intravenous formulation) by the University of Texas Southwestern Medical Center. A Phase II trial of ARQ 501 in combination with gemcitabine in treatment-naive unresectable pancreatic adenocarcinoma demonstrated disease stabilization but did not produce objective tumor responses sufficient for registration. Beyond anticancer applications, beta-lapachone exhibits anti-inflammatory activity through suppression of NF-kappaB-driven cytokine expression in activated macrophages and microglia, anti-obesity effects through stimulation of energy expenditure and white adipose tissue browning via NQO1-dependent NADH oxidation, and antimicrobial activity against Trypanosoma cruzi and Mycobacterium tuberculosis. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph